Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts less than Nifty Midcap 150 and 5.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon announced its Q1 FY26 results with consolidated revenue from operations growing ~15% year-on-year to Rs 39,419 million, driven by an 18% jump in the Biosimilars segment to Rs 24,578 million. However, the Generics segment swung to a loss of Rs 670 million from a profit of Rs 169 million, and consolidated operating margin compressed sharply from 25.25% to 21.02%. Consolidated profit attributable to shareholders fell steeply to Rs 274 million from Rs 4,367 million, largely because the year-ago quarter included a one-time gain of Rs 10,573 million from the sale of Biocon Biologics' India business to Eris Lifesciences. On a standalone basis, the company posted a net loss of Rs 83 million versus a Rs 9 million profit a year ago. The statutory auditor issued an unqualified limited review report on both standalone and consolidated results.
The headline earnings look weak, but the steep year-on-year decline is mostly a base-effect issue from the Eris sale gain in Q1 FY25. Underlying revenue growth and Biosimilars momentum are positives, while the Generics loss and margin compression are near-term concerns. The Rs 45,000 million QIP raised during the quarter strengthens the balance sheet (debt/equity improved to 0.49 from 0.64) and should ease subsidiary BBL's debt burden, supportive for the stock in the medium term.